You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRosoxacin
Accession NumberDB00817  (APRD00369)
TypeSmall Molecule
GroupsApproved
DescriptionRosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.
Structure
Thumb
Synonyms
Acrosoxacin
ROS
Rosoxacin
Rosoxacine
Rosoxacino
Rosoxacinum
Roxadyl
External Identifiers
  • TO 133
  • Win 35213
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EradacilSanofi-Aventis
Brand mixturesNot Available
SaltsNot Available
Categories
UNII3Y1OT3J4NW
CAS number40034-42-2
WeightAverage: 294.3047
Monoisotopic: 294.100442324
Chemical FormulaC17H14N2O3
InChI KeyXBPZXDSZHPDXQU-UHFFFAOYSA-N
InChI
InChI=1S/C17H14N2O3/c1-2-19-10-14(17(21)22)16(20)13-4-3-12(9-15(13)19)11-5-7-18-8-6-11/h3-10H,2H2,1H3,(H,21,22)
IUPAC Name
1-ethyl-4-oxo-7-(pyridin-4-yl)-1,4-dihydroquinoline-3-carboxylic acid
SMILES
CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1
Pharmacology
IndicationFor the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients.
Structured Indications Not Available
PharmacodynamicsRosoxacin is a nonfluorinated quinolone antibiotic. Its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Rosoxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.
Mechanism of actionRosoxacin binds to and inhibits the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNA gyrase subunit BProteinyes
inhibitor
Escherichia coli (strain K12)P0AES6 details
DNA topoisomerase 4 subunit AProteinyes
inhibitor
Escherichia coli (strain K12)P0AFI2 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Rosoxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rosoxacin.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Rosoxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Rosoxacin.Experimental, Illicit
AcarboseRosoxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Rosoxacin.Approved
AcenocoumarolRosoxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneAcetovanillone may increase the neuroexcitatory activities of Rosoxacin.Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Rosoxacin.Approved
AlbiglutideRosoxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Rosoxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rosoxacin.Experimental
AlogliptinRosoxacin may increase the hypoglycemic activities of Alogliptin.Approved
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Rosoxacin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rosoxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Rosoxacin.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Rosoxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Rosoxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Rosoxacin.Approved
ApremilastApremilast may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Rosoxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Rosoxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rosoxacin.Approved, Investigational
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rosoxacin.Approved, Vet Approved
Betulinic AcidBetulinic Acid may increase the neuroexcitatory activities of Rosoxacin.Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BromfenacBromfenac may increase the neuroexcitatory activities of Rosoxacin.Approved
BromocriptineRosoxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Rosoxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Rosoxacin.Approved
CalciumCalcium can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Nutraceutical
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium citrateCalcium citrate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CanagliflozinRosoxacin may increase the hypoglycemic activities of Canagliflozin.Approved
CarprofenCarprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the neuroexcitatory activities of Rosoxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
ChlorpropamideRosoxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Rosoxacin.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Rosoxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rosoxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rosoxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Rosoxacin.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rosoxacin.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Rosoxacin.Investigational
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Rosoxacin.Investigational
DapagliflozinRosoxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Rosoxacin.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rosoxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Rosoxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Rosoxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Rosoxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Rosoxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
DicoumarolRosoxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Rosoxacin.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Rosoxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Rosoxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Rosoxacin.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Rosoxacin.Approved
DisopyramideRosoxacin may increase the hypoglycemic activities of Disopyramide.Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Rosoxacin.Approved
DulaglutideRosoxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Rosoxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Rosoxacin.Approved
E6201E6201 may increase the neuroexcitatory activities of Rosoxacin.Investigational
EbselenEbselen may increase the neuroexcitatory activities of Rosoxacin.Investigational
EmpagliflozinRosoxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Rosoxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Rosoxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Rosoxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Rosoxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Rosoxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Ethyl biscoumacetateRosoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Rosoxacin.Approved
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Rosoxacin.Approved
ExenatideRosoxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Rosoxacin.Investigational
FenbufenFenbufen may increase the neuroexcitatory activities of Rosoxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved
Ferric CarboxymaltoseThe serum concentration of Rosoxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Rosoxacin can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Rosoxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
FloctafenineFloctafenine may increase the neuroexcitatory activities of Rosoxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Rosoxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Rosoxacin.Approved
FluindioneRosoxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rosoxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Rosoxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Rosoxacin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rosoxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Rosoxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Rosoxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rosoxacin.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Rosoxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Rosoxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rosoxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rosoxacin.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Rosoxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Rosoxacin.Approved, Investigational, Withdrawn
GliclazideRosoxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideRosoxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideRosoxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideRosoxacin may increase the hypoglycemic activities of Glyburide.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Rosoxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Rosoxacin.Investigational
HMPL-004HMPL-004 may increase the neuroexcitatory activities of Rosoxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rosoxacin.Approved, Vet Approved
IbuprofenIbuprofen may increase the neuroexcitatory activities of Rosoxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Rosoxacin.Approved
IndomethacinIndomethacin may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
Insulin AspartRosoxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirRosoxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineRosoxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineRosoxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanRosoxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproRosoxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Rosoxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Rosoxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Rosoxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Rosoxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Rosoxacin.Approved
LanreotideRosoxacin may increase the hypoglycemic activities of Lanreotide.Approved
Lanthanum carbonateThe serum concentration of Rosoxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
LiraglutideRosoxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Rosoxacin.Investigational
LornoxicamLornoxicam may increase the neuroexcitatory activities of Rosoxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateThe serum concentration of Rosoxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Rosoxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Rosoxacin.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Rosoxacin.Investigational
MecaserminRosoxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Rosoxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Rosoxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Rosoxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Rosoxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
MetforminRosoxacin may increase the hypoglycemic activities of Metformin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rosoxacin.Approved, Vet Approved
MifepristoneRosoxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolRosoxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Rosoxacin.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Rosoxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rosoxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Rosoxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Rosoxacin.Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Rosoxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
NateglinideRosoxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Rosoxacin.Investigational
NCX 4016NCX 4016 may increase the neuroexcitatory activities of Rosoxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Rosoxacin.Approved
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Rosoxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Rosoxacin.Approved, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Rosoxacin.Investigational
OctreotideRosoxacin may increase the hypoglycemic activities of Octreotide.Approved, Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Rosoxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Rosoxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Rosoxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Rosoxacin.Vet Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Rosoxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rosoxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Rosoxacin.Approved
PasireotideRosoxacin may increase the hypoglycemic activities of Pasireotide.Approved
PentamidineRosoxacin may increase the hypoglycemic activities of Pentamidine.Approved
PhenindioneRosoxacin may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonRosoxacin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
PioglitazoneRosoxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Rosoxacin.Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
PramlintideRosoxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Rosoxacin.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Rosoxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rosoxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Rosoxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rosoxacin.Experimental
ProbenecidThe serum concentration of Rosoxacin can be increased when it is combined with Probenecid.Approved
PropacetamolPropacetamol may increase the neuroexcitatory activities of Rosoxacin.Approved
PTC299PTC299 may increase the neuroexcitatory activities of Rosoxacin.Investigational
QuinaprilThe serum concentration of Rosoxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinineRosoxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinideRosoxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Rosoxacin.Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Rosoxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Rosoxacin.Investigational, Withdrawn
RosiglitazoneRosoxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalicylamideSalicylamide may increase the neuroexcitatory activities of Rosoxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Rosoxacin.Approved
SaxagliptinRosoxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SeratrodastSeratrodast may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
SevelamerSevelamer can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SitagliptinRosoxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SRT501SRT501 may increase the neuroexcitatory activities of Rosoxacin.Investigational
Strontium ranelateThe serum concentration of Rosoxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Rosoxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineRosoxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleRosoxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Rosoxacin.Approved
SulfisoxazoleRosoxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Rosoxacin.Approved
SunitinibRosoxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Withdrawn
TenoxicamTenoxicam may increase the neuroexcitatory activities of Rosoxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Rosoxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Rosoxacin.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Rosoxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Rosoxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Rosoxacin.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Rosoxacin.Approved
TolazamideRosoxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideRosoxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Rosoxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Rosoxacin.Approved
TranilastTranilast may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rosoxacin.Approved, Vet Approved
Trisalicylate-cholineTrisalicylate-choline may increase the neuroexcitatory activities of Rosoxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Rosoxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Rosoxacin.Approved, Investigational
WarfarinRosoxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved
ZileutonZileuton may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesJ01MB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9953
Blood Brain Barrier+0.8044
Caco-2 permeable+0.6365
P-glycoprotein substrateNon-substrate0.5522
P-glycoprotein inhibitor INon-inhibitor0.8418
P-glycoprotein inhibitor IINon-inhibitor0.7855
Renal organic cation transporterNon-inhibitor0.8055
CYP450 2C9 substrateNon-substrate0.7741
CYP450 2D6 substrateNon-substrate0.8696
CYP450 3A4 substrateNon-substrate0.7172
CYP450 1A2 substrateNon-inhibitor0.7953
CYP450 2C9 inhibitorNon-inhibitor0.864
CYP450 2D6 inhibitorNon-inhibitor0.9328
CYP450 2C19 inhibitorNon-inhibitor0.8731
CYP450 3A4 inhibitorNon-inhibitor0.9181
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7267
Ames testNon AMES toxic0.8588
CarcinogenicityNon-carcinogens0.8638
BiodegradationNot ready biodegradable0.9751
Rat acute toxicity2.3043 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9583
hERG inhibition (predictor II)Non-inhibitor0.8496
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point290 °CPhysProp
water solubility0.0209 mg/mL at 25 °CMEYLAN,WM et al. (1996)
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.102 mg/mLALOGPS
logP1.85ALOGPS
logP1.9ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)6.18ChemAxon
pKa (Strongest Basic)4.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area70.5 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity83.06 m3·mol-1ChemAxon
Polarizability30.8 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassQuinoline carboxylic acids
Direct ParentQuinoline carboxylic acids
Alternative Parents
Substituents
  • Quinoline-3-carboxylic acid
  • 4-phenylpyridine
  • Dihydroquinolone
  • Dihydroquinoline
  • Pyridine carboxylic acid or derivatives
  • Pyridine carboxylic acid
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Vinylogous amide
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Magnesium ion binding
Specific Function:
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
Gene Name:
gyrB
Uniprot ID:
P0AES6
Molecular Weight:
89949.195 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Zweerink MM, Edison A: Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601. [PubMed:3010848 ]
  4. Hirai K, Aoyama H, Suzue S, Irikura T, Iyobe S, Mitsuhashi S: Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother. 1986 Aug;30(2):248-53. [PubMed:3532944 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule. MukB stimulates the relaxation activity of topoisomerase IV and also has a modest effect on decatenation.
Gene Name:
parC
Uniprot ID:
P0AFI2
Molecular Weight:
83830.455 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Zweerink MM, Edison A: Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601. [PubMed:3010848 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23